Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.

You may also be interested in...



Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner

Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.

Wyeth Enters Manufacturing Agreement for Genentech's Herceptin

Bulk drug substance for Herceptin will be manufactured at Wyeth's Andover, Mass. facility. The companies should be familiar with this type of arrangement since Genentech signed a deal in 2002 to manufacture Wyeth/Amgen's Enbrel.

Genentech Expects To Miss Enbrel Manufacturing Deadlines; Amgen Will Not Reimburse Equipment

A Genentech SEC filing notes that milestones such as FDA approval of the manufacturing process would not be met in the agreed upon timeline.

Topics

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel